This glucose-lowering effect of aGLP1-E2 over GLP-1 is independent from the anti-obesity effect already described16 since in the present study the aGLP1-E2 conjugate did not decrease fat mass. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.